Acute Rescue Therapy for Seizure Clusters: Routes, Onset, and Readiness

Key Takeaways:

• Out-of-hospital rescue options differ mainly by route and onset, and route strongly influences whether a plan is actually used.
• Intranasal benzodiazepine formulations offer socially acceptable, rapid administration relative to rectal delivery; oral benzodiazepines are not FDA-approved for acute seizure episodes.
• A written seizure action plan, prompt administration at onset, and label-anchored dosing turn a prescription into a usable acute plan.

Breakthrough seizures and seizure clusters – acute repetitive seizures that are distinct from a patient's usual pattern – can escalate toward status epilepticus and are a common cause of emergency department visits and hospitalization if not treated promptly. Rescue therapy is the tool that interrupts a cluster before it progresses, yet whether a prescribed rescue medication is ever used often comes down to something practical: how it is given.¹

Route shapes real-world use

Three benzodiazepine rescue therapies are FDA-approved for seizure clusters: diazepam rectal gel, first approved in 1997, and 2 intranasal formulations – midazolam nasal spray (2019) and diazepam nasal spray (2020). All are typically administered by nonmedical care partners outside a healthcare facility, although appropriate patients may self-administer an intranasal formulation if they are able to recognize the start of a cluster and safely give the medication.²

Rectal administration, though effective, is socially difficult for older children, adolescents, and adults and is frequently avoided, particularly in public or school settings where privacy is limited.³

Intranasal delivery was developed specifically to preserve rapid absorption while offering a more discreet, easier route – a formulation challenge, since the goal was to match the systemic exposure of established routes without the barriers to use.⁴

Oral benzodiazepines are widely used off-label to interrupt seizures, but none are FDA-approved for acute seizure episodes, and swallowing is unreliable during an active event. For that reason, oral therapy is generally less preferred when a patient already has an FDA-approved rescue medication available.³

The real-world gap is measurable: Despite the availability of intranasal rescue therapies, real-world use remains limited by barriers including lack of caregiver training, school policies, and uncertainty about who should administer the medication.⁵

Matching dose and timing

Rescue therapy works best when administered promptly according to the patient’s individualized seizure action plan rather than waiting to see whether the cluster stops on its own. Patients should not exceed the maximum recommended frequency of use.⁶

Diazepam nasal spray is dosed by age and weight, with a second dose permitted no sooner than 4 hours after the first when needed. Midazolam nasal spray uses a single 5 mg dose, with an optional second 5 mg dose in the opposite nostril after 10 minutes. Caregivers should also know when to seek emergency medical care, including if a seizure continues despite rescue therapy, repeated seizures occur without recovery between them, or breathing or recovery is abnormal.^7,8

Underdosing and delayed administration are recognized barriers to effective acute treatment, so counseling patients and care partners on when and how to act is as important as the prescription itself.⁶

When rescue medication does not stop the cluster, when seizures continue without recovery between them, or when there are concerns about breathing, injury, or recovery, emergency medical services should be activated according to the patient’s seizure action plan.

Counseling on class safety

Patients and care partners should be counseled about common side effects such as drowsiness, sedation, and temporary impairment of coordination following rescue therapy. Benzodiazepine class effects apply across all rescue formulations. The most consequential is the boxed warning on concomitant use with opioids: The combination can cause profound sedation, respiratory depression, coma, and death, and co-prescribing should be reserved for patients without adequate alternatives.^7,9

The FDA has also cautioned clinicians not to reflexively withhold medications for opioid use disorder from patients taking benzodiazepines, since careful medication management can reduce risk. Handled as part of patient selection and safe-use counseling rather than as a reason to avoid rescue therapy, these considerations support appropriate prescribing. Patients should take rescue medication exactly as prescribed and contact their clinic if they have questions about when or how to use it.^7,10

Turning a prescription into a plan

The route that a patient and care partner will actually use, paired with a written, individualized seizure action plan and brief administration training, is what converts a rescue prescription into readiness. Because these therapies are given by nonmedical care partners – a family member, a roommate, a school nurse – the plan has to specify what constitutes a seizure cluster for that patient, when to give the first dose, when a second dose is appropriate, who should administer the medication, and when to call 9-1-1.²

Selecting a formulation with the patient's living situation and support in mind, and rehearsing when to give it, closes the gap between what is prescribed and what happens when a cluster begins.^2,6